74 filings
Page 2 of 4
424B5
i63mcu
9 Mar 23
Prospectus supplement for primary offering
6:31am
8-K
u635wg8atrkuot3hcup
6 Jan 23
Results of Operations and Financial Condition
7:01am
8-K
wieifq6h 0z2d637
31 Oct 22
Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022
9:00am
8-K
4kgbi z2ueh4
29 Sep 22
GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target
7:00am
8-K
xc1dmgdujc3l18
17 Jun 22
Submission of Matters to a Vote of Security Holders
7:00am
DEFA14A
i3ugruuuw 42t6x
28 Apr 22
Additional proxy soliciting materials
4:35pm
424B5
7j9k3py742 ibtk7i
18 Feb 22
Prospectus supplement for primary offering
5:01pm
S-8
qxjma4t
17 Feb 22
Registration of securities for employees
4:37pm
8-K
z61d67q7uf88a835n
9 Feb 22
Departure of Directors or Certain Officers
4:30pm
8-K
czy94y42agtx3it2pe
27 Jan 22
Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease
8:31am
8-K
z3vskel5ce51de
5 Jan 22
Regulation FD Disclosure
4:02pm
EFFECT
bt793g70 404m0
15 Nov 21
Notice of effectiveness
12:15am
CORRESP
byg4l9qsi286wg0h
10 Nov 21
Correspondence with SEC
12:00am
UPLOAD
by1ss
10 Nov 21
Letter from SEC
12:00am